RVPH Berita Valas

Reviva Pharma Announces Positive Data From DDI Study Of CYP3A4 Enzyme Effect On Brilaroxazine

Biopharmaceutical company Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced Thursday positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects.

RTTNews | 1047 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.16348	GBPUSD	1.33265	AUDUSD	0.65533
USDJPY	153.054	USDCAD	1.39977	USDCHF	0.79625